---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058082"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:06:24.978415+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M

## Summary
- Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.
- Life Sciences Services revenue rose 3% to $36.8M; BioStorage/BioServices up 9%.
- Net loss attributable to common stockholders was $20.9M ($0.43 per share) vs $7.6M ($0.16) a year ago.
- Full-year 2024 revenue guidance reaffirmed at $242-252M; CEO cites cost-reduction initiatives including workforce cuts.
- Cryoport now supports 15 commercial cell & gene therapies; 675 global clinical trials as of March 31, 2024.

## SEC filing metadata
- accession: 0001104659-24-058082
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/0001104659-24-058082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/tm2413756d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058082
- JSON: https://secwatch.observer/filing/0001104659-24-058082.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058082.txt

## Key facts
- Earnings Releases
  Cryoport, Inc. reported the first quarter ended March 31, 2024 results: revenue $54.6 million, net income $0.43 per share, EPS $0.43 per share. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $54.6 million
  - Net income: $0.43 per share
  - EPS: $0.43 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2413756d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/0001104659-24-058082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.